
Quarterly Result2 Nov 2026, 06:12 pm
Akums Reports 32% Revenue Growth in Q2 FY27
AI Summary
Akums Drugs & Pharmaceuticals Ltd. announced its consolidated financial results for Q2 FY27, reporting a significant 31.9% year-on-year revenue growth to ₹1,342 crore. EBITDA surged by 106% to ₹195 crore, with margins improving to 14.5%. Profit After Tax (PAT) grew by 168% to ₹115 crore, and PAT margin increased to 8.4%. The CDMO business was a key driver, with revenue up 38.6% to ₹1,115 crore. The company also expanded into color cosmetics manufacturing by acquiring Oriflame India's business for ₹56 crore. For H1 FY27, revenue grew 22.9% to ₹2,509 crore, EBITDA increased 65.3% to ₹369 crore, and PAT doubled to ₹216 crore.
Key Highlights
- Q2 FY27 revenue increased 31.9% YoY to ₹1,342 crore.
- EBITDA grew 106% YoY to ₹195 crore; PAT grew 168% YoY to ₹115 crore.
- CDMO business revenue rose 38.6% YoY to ₹1,115 crore.
- Acquired Oriflame India's manufacturing business for ₹56 crore.
- H1 FY27 revenue up 22.9% to ₹2,509 crore; PAT doubled to ₹216 crore.
Price Impact
More from AKUMS